Tentori F,Blayney MJ,Albert JM .2008 .Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis, 52(3) : 519-530.
Slatopolsky E,Gonzalez E,Martin K. Pathogenesis .2003 .and treatment of renal osteodystrophy. Blood Purif, 21(4-5) : 318-326.
Malberti F. Hyperphosphataemia .2013 .: treatment options. Drugs, 73(7) : 673-688.
Ketteler M,Biggar PH .2013 .Use of phosphate binders in chronic kidney disease. CurrOpinNephrolHypertens, 22(4) : 413-420.
Lopes AA,Tong L,Thumma J .2012 .Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pat- terns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis, 60(1) : 90-101.
Ho PM,Bryson CL,Rumsfeld JS .2009 .Medication adherence: its importance in cardiovascular outcomes. Circulation, 119 : 3028-35.
Arenas MD,Malek T,Alvarez-Ude F,Gil MT,Moledous A,Reig-Ferrer A .2010 .Spanish [with English abstract]. Nefrologia, 30(5) : 522-530.
Isakova T,Nickolas TL,Denburg M .2017 .- tary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis, 70(6) : 737-751.
Schmid H,Hartmann B,Schiffl H B .2009 .Adherence to prescribed oral medica- tion in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res, 14(5) : 185-190.
Karamanidou C,Clatworthy J,Weinman J,Horne R. .2008 .A systematic review of the prevalence and determinants of nonadherence to phos- phate binding medication in patients with end-stage renal disease. BMC Nephrol, 9 : 2.
Covic A,Rastogi A .2013 .Hyperphosphatemia in patients with ESRD: assess- ing the current evidence linking outcomes with treatment adherence. BMC Nephrol, 14(1) : 153.
Ghimire S,Castelino RL,Lioufas NM,Peterson GM,Zaidi ST .2015 .Nonad- herence to medication therapy in haemodialysis patients: a systematic review. PLoS One, 10(12) : e0144119.
Kalantar-Zadeh K .2013 .Patient education for phosphorus management in chronic kidney disease. Patient Prefer Adherence, 7 : 379-390.
Waheed AA,Pedraza F,Lenz O,Isakova T. .2013 .Phosphate control in end- stage renal disease: barriers and opportunities. Nephrol Dial Transplant, 28(12) : 2961-2968.
Mathes T,Jaschinski T,Pieper D. .2014 .Adherence influencing factors - a systematic review of systematic reviews. Archives of public health, 72(1) : 37.
Falah H. Hadi1 ,Al-Asraf .2021 .Adherence to Phosphate Binder Therapy in Patient with Chronic Kidney Disease a Cross-Sectional Study. , : Iraq1.
Fusco N,Sils B,Graff JS,Kistler K,Ruiz K .2023 .Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: A systematic literature review. Journal of Managed Care & Specialty Pharmacy, 29(1) : 4-16.
Ahjel S.W. .2020 .Antineoplastic Effect of New Synthesized Compounds of 2-Thiouracil Sulfonamide Derivatives against Ovarian and Breast Carcinoma Cells" In Vitro Study". Systematic Reviews in Pharmacy, 11(4) : .
Al-Huesini Abbas,L.M. Abbas .2019 .. DMF Ameliorating Cerebral Ischemia/Reperfusion Injury in Meal Rats. Systematic Reviews in Pharmacy, 10(1) : .